Synthesis and antiproliferative activity in vitro of diacetylenic thioquinolines

Pharmazie

Volumn 61, Issue 9, 2006, Pages 742-746

  Mol W ^a   Naczynski A ^a   Boryczka, S ^a   Wietrzyk, J ^b   Opolski, A ^b,c  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^c JAN DLUGOSZ UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BIS (3 METHYLTHIO 4 QUINOLINYLSELENO) 2 BUTYNE; 1,4 BIS (3 PROPARGYLTHIO 4 QUINOLINYLSELENO) 2 BUTYNE; 3 (2 BUTYNYLTHIO) 4 (2 BUTYNYLSELENO)QUINOLINE; 3 (2 BUTYNYLTHIO) 4 (PROPARGYLSELENO)QUINOLINE; 3 (2 BUTYNYLTHIO) 4 (PROPARGYLTHIO)QUINOLINE; 3 (PROPARGYLTHIO) 4 (PROPARGYLSELENO)QUINOLINE; 3,4 DI(2 BUTYNYLTHIO)QUINOLINE; 3,4 DI(PROPARGYLTHIO)QUINOLINE; 4 (2 BUTYNYLSELENO) 3 (PROPARGYLTHIO)QUINOLINE; 4 (2 BUTYNYLSELENO) 3 METHYLTHIOQUINOLINE; 4 (2 BUTYNYLTHIO) 3 (PROPARGYLTHIO)QUINOLINE; 4 (2 BUTYNYLTHIO) 3 METHYLTHIOQUINOLINE; 4 (4 BROMO 2 BUTYLNYLTHIO) 3 (2 BUTYNYLTHIO)QUINOLINE; 4 (4 BROMO 2 BUTYLNYLTHIO) 3 (2 PROPARGYLTHIO)QUINOLINE; 4 CHLORO 3 (2 BUTYNYLTHIO)QUINOLINE; CISPLATIN; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA; MELANOMA; MOUSE; NONHUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDICATORS AND REAGENTS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; QUINOLINES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROPHOTOMETRY, ULTRAVIOLET; TETRAZOLIUM SALTS; THIAZOLES;

EID: 33749008520     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Almenningen A, Bastiansen O, Tretterberg M (1961) An electron diffraction investigation of the molecular structure of butatriene. Acta Chem Scand 15: 1557-1562.
2. Boryczka S, Kulig K, Malawska B (2003) RP TLC Determination of the lipophilicity of anticancer active propargyl thioquinolines. J Planar Chromatogr 16: 117-120.
3. Boryczka S, Wietrzyk J, Nasulewicz A, Pełczyńska M, Opolski A (2002a) New propargyl thioquinolines - synthesis, antiproliferative activity in vitro and structure-activity relationships. Pharmazie 57: 733-739.
4. Boryczka S, Wietrzyk J, Opolski A (2002b) Synthesis and antiproliferative activity in vitro of new propargyl thioquinolines. Pharmazie 57: 151-154.
5. Grissom JW, Gunawardena GU, Klingberg D, Huang D (1996) The chemistry of enediynes, enyne allenes and related compounds. Tetrahedron 52: 6453-6518.
6. Jones GB, Fouad FS (2002) Designed enediyne antitumor agents. Curr Pharm Design 8: 2415-2440.
7. Kumar D, David WM, Kerwin SM (2001) N-Propargyl-2-alkynylbenzothiazolium aza-enediyne: role of the 2-alkynylbenzothiazolium functionality in DNA cleavage. Bioorg Med Chem Lett 11: 2971-2974.
8. Machinek R, Lüttke W (1975) A convenient preparation of α,α′-dibromoalkynes from alkynediols. Synthesis 255-256.
9. Maślankiewicz A, Boryczka S (1993) Reactions of 4-methoxy-3-quinolinyl and 1,4-dihydro-4-oxo-3-quinolinyl sulfides aiming at the synthesis of 4-chloro-3-quinolinyl sulfides. J Heterocycl. Chem 30: 1623-1628.
10. Nicolaou KC, Dai W-M (1991) Chemistry and biology of the enediyne anticancer antibiotics. Angew Chem Int Ed Engl 30: 1387-1416.
11. Rawat DS, Benites PJ, Incarvito CD, Rheingold AL, Zaleski JM (2001) The contribution of ligand flexibility to metal center geometry modulated thermal cyclization of conjugated pyridine and quinoline metalloenediyne of copper (I) and copper (II). Inorg Chem 40: 1846-1857.
12. Skehan P, Storeng R, Scudiero D, Monks A, Mcmachon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyol MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112.
13. Wu M-J, Lin C-F, Chen H-T, Duh T-H, Wang S-S, Hsu S-C (1996) Molecular design, chemical synthesis and biological studies of novel enediynes related to dynemicin A. Bioorg Med Chem Lett 6: 2183-2186.